About Index Trending news
Analyze
Pricing
Jounce Therapeutics

Jounce Therapeutics

Work at Jounce Therapeutics? Add yourself to this profile

Jounce Therapeutics

Jounce Therapeutics is developing cancer immune-therapies to harness the immunesystem to attack cancerous cells and tumors.
Edit Profile
More info

Elsewhere

Also headquartered in Cambridge

MIT MIT Raspberry Pi Raspberry Pi ARM ARM Xconomy Xconomy Mobile.co Mobile.co HubSpot HubSpot nuTonomy nuTonomy Biogen Biogen Sarepta Therapeutics Sarepta Therapeutics General Catalyst General Catalyst

Companies in the same industry

Neurotrack Neurotrack Chimerix Chimerix Sonoma Orthopedics Sonoma Orthopedics Amplion Amplion Atlas Genetics Atlas Genetics Care Point Software Care Point Software Nervana Nervana Xagenic Inc. Xagenic Inc. IntelliCyt IntelliCyt Andrew Alliance Andrew Alliance

Alexa global traffic share

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2
Add info
Latest funding
IPO
$102,000,000
Venture capital (Series B)
$56,000,000
Redmile Group, Foresite Capital, Wellington Management, +5
Employees

Team size

50+
Locations
HQ
Cambridge, United States
Headquarters
$102,000,000 IPO
Xconomy

Jounce Gets $102M As Biotech IPOs Gain Steam in ’17

Stock markets Earnings
Jounce Therapeutics
Jounce Therapeutics
$56,000,000 Venture capital (Series B)
VentureWire

The Daily Startup: Jounce Therapeutics Raises $56M as Immunotherapy Stays Hot

Funding
Jounce Therapeutics
Jounce Therapeutics